The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.

ABSTRACT:

Background

Recent advancements in the clinical management of metastatic prostate cancer include several costly therapies and diagnostic tests. The objective of this study was to provide updated information on the cost to payers attributable to metastatic prostate cancer among men aged 18 to 64 years with employer-sponsored health plans and men aged 18 years or older covered by employer-sponsored Medicare supplement insurance.

Methods

By using Merative MarketScan commercial and Medicare supplemental data for 2009-2019, the authors calculated differences in spending between men with metastatic prostate cancer and their matched, prostate cancer-free controls, adjusting for age, enrollment length, comorbidities, and inflation to 2019 US dollars.

Results

The authors compar

SUBMITTER: Horny M 

PROVIDER: S-EPMC10527879 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature